

POSTER PRESENTATION

Open Access

Temporal changes of serum cytokine/chemokine levels in patients of Nakajo-Nishimura syndrome treated with tocilizumab

N Kanazawa^{1*}, Y Nakatani¹, Y Inaba¹, K Kunimoto¹, F Furukawa¹, F Ozaki²

From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases Dresden, Germany. 30 September - 3 October 2015

In Nakajo-Nishimura syndrome (NNS), proteasome disability due to a loss-of-function *PSMB8* mutation induces storage of ubiquitinated proteins and overproduction of inflammatory cytokines and chemokines. However, the precise mechanisms causing complex phenotypes of the disease, including pernio-like eruptions, lipodystrophy and calcification of basal ganglia, is mostly unclear. As IL-6 overproduction in association with p38 hyperactivation was supposed to have a role in NNS (Arima *et al*, PNAS 2011), tocilizumab, a monoclonal antibody for IL-6 receptor, has recently been applied for two patients with NNS after informed consents were obtained. Decreased serum CRP and CPK levels in both patients and improved myalgia and arthralgia in one patient have been observed, whereas none of decrease in serum LDH level or improvement of fever and eruptions have been achieved. By analysis of serum cytokine/chemokine levels, IL-6, G-CSF and MCP-1 levels have changed in accordance to the CRP level, whereas IP-10 has shown constantly high levels independent of the CRP level. Furthermore, both the patients-derived peripheral blood monocytes and monocytes differentiated from a patient-derived iPS cells produced higher level of IP-10 than control cells after IFN γ stimulation. These findings suggest that monocyte-derived IP-10 has a major role in pathogenesis of the sustained/progressing phenotypes in NNS.

Authors' details

¹Wakayama Medical University, Department of Dermatology, Wakayama, Japan. ²Kyoto University, Center for iPS Cell Research and Application, Kyoto, Japan.

¹Wakayama Medical University, Department of Dermatology, Wakayama, Japan

Full list of author information is available at the end of the article

Published: 28 September 2015

doi:10.1186/1546-0096-13-S1-P169

Cite this article as: Kanazawa *et al.*: Temporal changes of serum cytokine/chemokine levels in patients of Nakajo-Nishimura syndrome treated with tocilizumab. *Pediatric Rheumatology* 2015 **13**(Suppl 1):P169.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

